Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd. (NLSP) generates news that reflects both its historical role as a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders and its transformation through a merger with Kadimastem Ltd. into NewcelX Ltd. Company announcements and SEC filings describe a shift from a pure CNS small-molecule focus toward an integrated platform that also encompasses cell therapies for neurodegenerative and metabolic diseases.
News items associated with NLSP and the subsequent NewcelX name cover several recurring themes. Transaction-related updates include the approval and closing of the merger with Kadimastem, the 1-for-10 reverse share split, the name change to NewcelX Ltd., and the transition of the Nasdaq listing from NLSP to the new symbol NCEL. These releases explain the exchange ratio between NLS and Kadimastem shareholders, the resulting ownership structure, and the rationale for combining small-molecule and cell therapy pipelines.
Pipeline and R&D news highlights programs such as AstroRx® for ALS, the IsletRx stem cell–derived therapy for insulin-dependent diabetes, and the DOXA small-molecule platform for CNS and neurodegenerative indications. Announcements describe preclinical and clinical milestones, intellectual property developments such as a Hong Kong patent for IsletRx-related cell-selection and enrichment technology, and expansion of the DOXA platform through the AEX-6xx series developed with Aexon Labs.
Additional coverage includes strategic collaborations and governance updates. Examples are the collaboration framework between Kadimastem and TargetGene for gene-edited cell therapies, continued support from the BIRD Foundation for the ITOL-102 diabetes program, and appointments to leadership roles and the Scientific Advisory Board at NewcelX. For readers tracking NLSP-related news, this page offers a consolidated view of historical NLS announcements and the ongoing evolution of the combined company under the NewcelX name and NCEL ticker.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced new study data confirming mazindol's mechanism of action as an Orexin-2 receptor (OX2R) agonist, essential for treating narcolepsy. In a pre-clinical study, genetically modified mice demonstrated significantly reduced sensitivity to mazindol, reinforcing its potent neurochemical activity. Ongoing studies aim to expand on these findings, emphasizing mazindol's potential dual mechanism of action in addressing narcolepsy's core symptoms. The company remains committed to developing Quilience®, a controlled-release formulation of mazindol, with hopes of improving treatment efficacy.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) has appointed Dr. Silvia Panigone as Chief Operating Officer, effective immediately. Dr. Panigone brings over 25 years of experience in healthcare, having previously led ADYA Consulting and served in various roles within international pharmaceutical companies. Her expertise will be pivotal as NLS advances its lead drug, Quilience®, designed for treating narcolepsy. The company aims to secure IND approval in the U.S. and move Quilience into clinical stages, addressing significant unmet medical needs in CNS disorders.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced the issuance of Canadian Patent No. 3016852 for its controlled-release mazindol formulation aimed at treating ADHD and related disorders. This patent provides intellectual property protection for a multilayer tablet combining immediate and sustained-release properties. CEO Alex Zwyer emphasized the potential of Quilience® to address unmet needs in narcolepsy treatment. NLS's European patent application is also progressing, with a Phase 2 clinical study for Quilience planned. The company holds Orphan Drug Designations for this drug in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NLSP) has entered a License Agreement with Novartis Pharma AG, securing exclusive rights in the U.S. for all data related to the NDA for Sanorex® (mazindol). This agreement also extends non-exclusively outside the U.S., excluding Japan. The CEO stated this acquisition may streamline clinical processes and reduce costs, enhancing the development of Quilience®, a controlled release formulation of mazindol aimed at treating narcolepsy and related sleep disorders. Quilience has received Orphan Drug Designation in the U.S. and Europe.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage biopharmaceutical company, announced CEO Alex Zwyer will present at key investor conferences. The events include the Livingston Securities Healthcare and Emerging Growth CEO Series on February 25, 2021, at 11:30 AM ET and the Maxim 2021 Emerging Growth Virtual Conference on March 17, 2021. NLS is focused on developing treatments for rare central nervous system disorders, with its lead candidate Quilience®, a formulation of mazindol, targeting narcolepsy. The company has successfully completed a Phase 2 study for ADHD and holds Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced the closing of its initial public offering, raising approximately $20.0 million by selling 4,819,277 units at $4.15 per unit. Each unit consists of one common share and one warrant, both of which began trading on the Nasdaq Capital Market on January 29, 2021. The warrants are exercisable immediately at the same price and expire in five years. NLS also granted underwriters a 45-day option to purchase additional shares and warrants. The funds will support the development of their lead product candidate, Quilience®, for treating narcolepsy.
NLS Pharmaceutics Ltd. has priced its initial public offering (IPO) of 4,819,277 units at $4.15 per unit, aiming to raise approximately $20.0 million before expenses. Each unit includes one common share and one warrant, with trading expected to commence on January 29, 2021, under symbols NLSP and NLSPW. The offering will close on February 2, 2021, subject to customary conditions. Maxim Group LLC and Brookline Capital Markets are managing the offering, which includes a 45-day option for underwriters to purchase additional shares.